New York, New York--(Newsfile Corp. - August 19, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Ardelyx, Inc. ("Ardelyx") (NASDAQ: ARDX) between August 6, 2020 and July 19, 2021.
If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/ardelyx-inc-loss-submission-form?prid=18739&wire=5
Allegations against ARDX include that the Company made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.
If you suffered a loss in Ardelyx you have until September 28, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/93814
